Title of article
Acute and Sub-chronic Toxicity (90-Day) Study of Swamala (SWA)® in Wistar Rats
Author/Authors
Nilakash، S. نويسنده Shree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai, Maharashtra, India , , Jonnalagadda، V. G. نويسنده Shree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai, Maharashtra, India , , Chawda، M. B. نويسنده Shree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai, Maharashtra, India , , Thakur، N. K. نويسنده , , Vahalia، M. K نويسنده Shree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai, Maharashtra, India , , Shitut، S. S نويسنده Shree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai, Maharashtra, India ,
Issue Information
فصلنامه با شماره پیاپی سال 2014
Pages
9
From page
52
To page
60
Abstract
Background: Swamala (SWA)® is an Ayurvedic proprietary product used in the
treatment of general debility and in immune-compromised conditions. Despite its
usefulness, there is no published data on toxicity profile of SWA®. Objective: The main
objective of the present study was to evaluate safety of SWA® in an acute and 900 day
repeated dose toxicity studey in Wistar rats. Methods: SWA® at the doses of 0, 3, 6,
and 15 g/kg was administered for 90 consecutive days. Body weights and feed
consumption were recorded and analyzed. At termination of the study rats were
sacrificed and observed for gross pathological changes. All organ parts were collected,
weighed and preserved for histopathological examination and blood was collected from
retro-orbital sinus for clinical biochemical analysis. Results: After 90 days of oral
administration SWA® did not show any gross toxicological signs and histopathology
also when compared with normal. All animals in Group IV showed significant increase
in body weight as compared to that of control group animals. No mortality was
observed throughout the period. Conclusion: Finally, it was concluded that SWA®
having no toxico-pathological effects at a dose of 15 g/Kg which is equivalent to five
times the therapeutic dose administered orally for 90 days.
Journal title
Pharmaceutical Sciences
Serial Year
2014
Journal title
Pharmaceutical Sciences
Record number
2211514
Link To Document